Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2018-05-21 13:07 CEST (UTC+2h)
 

Choice of comparator [Design Issues]

posted by Mikkabel - Belgium, 2018-01-23 17:29  - Posting: # 18277
Views: 1,457

Dear All,

I have a question regarding the choice of the comparator to be chosen in a classical CO study.

To summarize, my company get the marketing autorisation for a generic product (Tablet, called T1) based on a PK study demonstrating the bioequivalence versus the original product (called R).
Furthermore, according to the originator's SPC, the recommended dose is 1 or 2 Tablets.

Therefore, the R&D branch of my company would like to develop a new dosage of the product T1 corresponding to 2 tablets of the original product (R) in order to increase patients' comfort and compliance with the treatment (only quantitative change to the active substance). The new proposed dosage will be called T2.

Could you please advise which design should be better for a PK study:Hope it clear.....;-)

Thank you in advance for your answer,

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
18,269 posts in 3,882 threads, 1,161 registered users;
13 users online (1 registered, 12 guests).

Science is wonderfully equipped to answer the question “How?”
but it gets terribly confused when you ask the question “Why?”    Erwin Chargaff

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
XHTML/CSS RSS Feed